From chronic to curable: Twice-yearly shot shows near-total HIV eradication
SMRTR summary
A new injectable medication, Lenacapavir, shows promise in HIV prevention with 96% efficacy when given twice yearly. In a clinical trial, only 2 out of 2,179 participants receiving Lenacapavir contracted HIV, compared to 9 out of 1,086 taking daily oral pills. This advancement could significantly improve HIV prevention, especially for those struggling with daily medication adherence, with potential FDA approval by 2025.
SMRTR provides this summary for quick context. The original article belongs to Interesting Engineering.
Read the original article